Skip to main content
SpringerLink
Log in

The effect of growth hormone replacement in patients with hypopituitarism on pituitary tumor recurrence, secondary cancer, and stroke

  • Meta-Analysis
  • Published:
Endocrine Aims and scope Submit manuscript

Abstract

Growth hormone replacement therapy has benefits for patients with hypopituitarism. The safety profile in regard to tumor recurrence or progression, development of secondary malignancies, or cerebrovascular stroke is still an area of debate. A comprehensive search of multiple databases—MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, and Scopus was conducted through August 2015. Eligible studies that evaluated long-term adverse events in adult patients with hypopituitarism treated with growth hormone replacement therapy and reported development of pituitary tumor recurrence or progression, secondary malignancies, or cerebrovascular stroke were selected following a predefined protocol. Reviewers, independently and in duplicate, extracted data and assessed the risk of bias. Random-effects meta-analysis was used to pool relative risks and 95 % confidence intervals. We included 15 studies (published 1995–2015) that reported on 46,148 patients. Compared to non-replacement, growth hormone replacement therapy in adults with hypopituitarism was not associated with statistically significant change in pituitary tumor progression or recurrence (relative risk, 0.77; 95 % confidence interval, 0.53–1.13) or development of secondary malignancy (relative risk, 0.99; 95 % confidence interval, 0.70–1.39). In two retrospective studies, there was higher risk of stroke in patients who did not receive replacement (relative risk, 2.07; 95 % confidence interval, 1.51–2.83). The quality of evidence is low due to study limitations and imprecision. This systematic review and meta-analysis supports the overall safety of growth hormone therapeutic use in adults with hypopituitarism with no clear evidence of increased risk of pituitary tumor recurrence, malignancy, or stroke.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. A.A. Toogood, C.G. Beardwell, S.M. Shalet, The severity of growth hormone deficiency in adults with pituitary disease is related to the degree of hypopituitarism. Clin. Endocrinol. 41(4), 511–516 (1994)

    Article  CAS  Google Scholar 

  2. K. Stochholm, C.H. Gravholt, T. Laursen, J.O. Jorgensen, P. Laurberg, M. Andersen, L.O. Kristensen, U. Feldt-Rasmussen, J.S. Christiansen, M. Frydenberg, A. Green, Incidence of GH deficiency—a nationwide study. Eur. J. Endocrinol. 155(1), 61–71 (2006). doi:10.1530/eje.1.02191

    Article  CAS  PubMed  Google Scholar 

  3. A. Agha, M. Sherlock, S. Brennan, S.A. O’Connor, E. O’Sullivan, B. Rogers, C. Faul, D. Rawluk, W. Tormey, C.J. Thompson, Hypothalamic-pituitary dysfunction after irradiation of nonpituitary brain tumors in adults. J. Clin. Endocrinol. Metab. 90(12), 6355–6360 (2005). doi:10.1210/jc.2005-1525

    Article  CAS  PubMed  Google Scholar 

  4. M.D. Littley, S.M. Shalet, C.G. Beardwell, S.R. Ahmed, G. Applegate, M.L. Sutton, Hypopituitarism following external radiotherapy for pituitary tumours in adults. Quat. J. Med. 70(262), 145–160 (1989)

    CAS  Google Scholar 

  5. L. Lonn, H. Kvist, U. Grangard, B.A. Bengtsson, L. Sjostrom, CT-determined body composition changes with recombinant human growth hormone treatment to adults with growth hormone deficiency. Basic. Life. Sci. 60, 229–231 (1993)

    CAS  PubMed  Google Scholar 

  6. R. Abs, U. Feldt-Rasmussen, A.F. Mattsson, J.P. Monson, B.A. Bengtsson, M.I. Goth, P. Wilton, M. Koltowska-Haggstrom, Determinants of cardiovascular risk in 2589 hypopituitary GH-deficient adults—a KIMS database analysis. Eur. J. Endocrinol. 155(1), 79–90 (2006). doi:10.1530/eje.1.02179

    Article  CAS  PubMed  Google Scholar 

  7. R.J. Irving, M.N. Carson, D.J. Webb, B.R. Walker, Peripheral vascular structure and function in men with contrasting GH levels. J. Clin. Endocrinol. Metab. 87(7), 3309–3314 (2002). doi:10.1210/jcem.87.7.8655

    Article  CAS  PubMed  Google Scholar 

  8. V. Markussis, S.A. Beshyah, C. Fisher, K.H. Parker, A.N. Nicolaides, D.G. Johnston, Abnormal carotid arterial wall dynamics in symptom-free hypopituitary adults. Eur. J. Endocrinol. 136(2), 157–164 (1997)

    Article  CAS  Google Scholar 

  9. J.O. Johansson, K. Landin, G. Johannsson, L. Tengborn, B.A. Bengtsson, Long-term treatment with growth hormone decreases plasminogen activator inhibitor-1 and tissue plasminogen activator in growth hormone-deficient adults. Thromb. Haemost. 76(3), 422–428 (1996)

    CAS  PubMed  Google Scholar 

  10. J. Kvasnicka, J. Marek, T. Kvasnicka, V. Weiss, M. Markova, J. Stepan, A. Umlaufova, Increase of adhesion molecules, fibrinogen, type-1 plasminogen activator inhibitor and orosomucoid in growth hormone (GH) deficient adults and their modulation by recombinant human GH replacement. Clin. Endocrinol. 52(5), 543–548 (2000). doi:10.1046/j.1365-2265.2000.01002.x

    Article  CAS  Google Scholar 

  11. J.C. Carel, E. Ecosse, F. Landier, D. Meguellati-Hakkas, F. Kaguelidou, G. Rey, J. Coste, Long-term mortality after recombinant growth hormone treatment for isolated growth hormone deficiency or childhood short stature: preliminary report of the French SAGhE study. J. Clin. Endocrinol. Metab. 97(2), 416–425 (2012). doi:10.1210/jc.2011-1995jc.2011-1995

    Article  CAS  PubMed  Google Scholar 

  12. R.C. Gaillard, A.F. Mattsson, A.C. Akerblad, B.A. Bengtsson, J. Cara, U. Feldt-Rasmussen, M. Koltowska-Haggstrom, J.P. Monson, B. Saller, P. Wilton, R. Abs, Overall and cause-specific mortality in GH-deficient adults on GH replacement. Eur. J. Endocrinol. 166(6), 1069–1077 (2012). doi:10.1530/EJE-11-1028EJE-11-1028

    Article  CAS  PubMed  Google Scholar 

  13. J. Svensson, B.A. Bengtsson, T. Rosen, A. Oden, G. Johannsson, Malignant disease and cardiovascular morbidity in hypopituitary adults with or without growth hormone replacement therapy. J. Clin. Endocrinol. Metab. 89(7), 3306–3312 (2004). doi:10.1210/jc.2003-03160189/7/3306

    Article  CAS  PubMed  Google Scholar 

  14. M.N. Pollak, E.S. Schernhammer, S.E. Hankinson, Insulin-like growth factors and neoplasia. Nat. Rev. Cancer. 4(7), 505–518 (2004). doi:10.1038/nrc1387nrc1387

    Article  CAS  PubMed  Google Scholar 

  15. A. Wolk, C.S. Mantzoros, S.O. Andersson, R. Bergstrom, L.B. Signorello, P. Lagiou, H.O. Adami, D. Trichopoulos, Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. J. Natl. Cancer. Inst. 90(12), 911–915 (1998)

    Article  CAS  Google Scholar 

  16. H. Yu, M.R. Spitz, J. Mistry, J. Gu, W.K. Hong, X. Wu, Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis. J. Natl. Cancer. Inst. 91(2), 151–156 (1999)

    Article  CAS  Google Scholar 

  17. S.E. Hankinson, W.C. Willett, G.A. Colditz, D.J. Hunter, D.S. Michaud, B. Deroo, B. Rosner, F.E. Speizer, M. Pollak, Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet. 351(9113), 1393–1396 (1998). doi:10.1016/S0140-6736(97)10384-1

    Article  CAS  PubMed  Google Scholar 

  18. B. Delhougne, C. Deneux, R. Abs, P. Chanson, H. Fierens, P. Laurent-Puig, I. Duysburgh, A. Stevenaert, A. Tabarin, J. Delwaide, G. Schaison, J. Belaiche, A. Beckers, The prevalence of colonic polyps in acromegaly: a colonoscopic and pathological study in 103 patients. J. Clin. Endocrinol. Metab. 80(11), 3223–3226 (1995). doi:10.1210/jcem.80.11.7593429

    Article  CAS  PubMed  Google Scholar 

  19. A.G. Renehan, S.,T. O’Dwyer, S.M. Shalet, Colorectal neoplasia in acromegaly: the reported increased prevalence is overestimated. Gut. 46(3), 440–441 (2000)

    Article  CAS  Google Scholar 

  20. J.E. Brunner, C.C. Johnson, S. Zafar, E.L. Peterson, J.F. Brunner, R.C. Mellinger, Colon cancer and polyps in acromegaly: increased risk associated with family history of colon cancer. Clin. Endocrinol. 32(1), 65–71 (1990)

    Article  CAS  Google Scholar 

  21. S. Ezzat, C. Strom, S. Melmed, Colon polyps in acromegaly. Ann. Intern. Med. 114(9), 754–755 (1991)

    Article  CAS  Google Scholar 

  22. D. Moher, A. Liberati, J. Tetzlaff, D.G. Altman, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 339, b2535 (2009). doi:10.1136/bmj.b2535bmj.b2535

    Article  PubMed  PubMed Central  Google Scholar 

  23. R. DerSimonian, N. Laird, Meta-analysis in clinical trials. Control. Clin. Trials. 7(3), 177–188 (1986)

    Article  CAS  Google Scholar 

  24. J.P. Higgins, S.G. Thompson, Quantifying heterogeneity in a meta-analysis. Stat. Med. 21(11), 1539–1558 (2002). doi:10.1002/sim.1186

    Article  PubMed  Google Scholar 

  25. B.C. Wallace, I.J. Dahabreh., T.A. Trikalinos, J. Lau, P. Trow, C.H. Schmid, Closing the gap between methodologists and end-users: R as a computational back-end. J. Stat. Softw. 49(i05) (2012)

  26. M.H. Murad, V.M. Montori, J.P. Ioannidis, R. Jaeschke, P.J. Devereaux, K. Prasad, I. Neumann, A. Carrasco-Labra, T. Agoritsas, R. Hatala, M.O. Meade, P. Wyer, D.J. Cook, G. Guyatt, How to read a systematic review and meta-analysis and apply the results to patient care: users’ guides to the medical literature. JAMA. 312(2), 171–179 (2014). doi:10.1001/jama.2014.55591886196

    Article  CAS  PubMed  Google Scholar 

  27. B.A. Swiglo, M.H. Murad, H.J. Schunemann, R. Kunz, R.A. Vigersky, G.H. Guyatt, V.M. Montori, A case for clarity, consistency, and helpfulness: state-of-the-art clinical practice guidelines in endocrinology using the grading of recommendations, assessment, development, and evaluation system. J. Clin. Endocrinol. Metab. 93(3), 666–673 (2008). doi:10.1210/jc.2007-1907

    Article  CAS  PubMed  Google Scholar 

  28. C.C. van Bunderen, I.C. van Nieuwpoort, L.I. Arwert, M.W. Heymans, A.A. Franken, H.P. Koppeschaar, A.J. van der Lely, M.L. Drent, Does growth hormone replacement therapy reduce mortality in adults with growth hormone deficiency? Data from the dutch national registry of growth hormone treatment in adults. J. Clin. Endocrinol. Metab. 96(10), 3151–3159 (2011). doi:10.1210/jc.2011-1215jc.2011-1215

    Article  PubMed  Google Scholar 

  29. A.J. Swerdlow, R.E. Reddingius, C.D. Higgins, H.A. Spoudeas, K. Phipps, Z. Qiao, W.D. Ryder, M. Brada, R.D. Hayward, C.G. Brook, P.C. Hindmarsh, S.M. Shalet, Growth hormone treatment of children with brain tumors and risk of tumor recurrence. J. Clin. Endocrinol. Metab. 85(12), 4444–4449 (2000). doi:10.1210/jcem.85.12.7044

    Article  CAS  PubMed  Google Scholar 

  30. G. Frajese, W.M. Drake, R.A. Loureiro, J. Evanson, D. Coyte, D.F. Wood, A.B. Grossman, G.M. Besser, J.P. Monson, Hypothalamo-pituitary surveillance imaging in hypopituitary patients receiving long-term GH replacement therapy. J. Clin. Endocrinol. Metab. 86(11), 5172–5175 (2001). doi:10.1210/jcem.86.11.8018

    Article  CAS  PubMed  Google Scholar 

  31. N.C. van Varsseveld, C.C. van Bunderen, A.A. Franken, H.P. Koppeschaar, A.J. van der Lely, M.L. Drent, Tumor recurrence or regrowth in adults with nonfunctioning pituitary adenomas using GH replacement therapy. J. Clin. Endocrinol. Metab. 100(8), 3132–3139 (2015). doi:10.1210/jc.2015-1764

    Article  CAS  PubMed  Google Scholar 

  32. P. Maison, S. Griffin, M. Nicoue-Beglah, N. Haddad, B. Balkau, P. Chanson, Impact of growth hormone (GH) treatment on cardiovascular risk factors in GH-deficient adults: a metaanalysis of blinded, randomized, placebo-controlled trials. J. Clin. Endocrinol. Metab. 89(5), 2192–2199 (2004). doi:10.1210/jc.2003-030840

    Article  CAS  PubMed  Google Scholar 

  33. M. Bex, R. Abs, D. Maiter, A. Beckers, G. Lamberigts, R. Bouillon, The effects of growth hormone replacement therapy on bone metabolism in adult-onset growth hormone deficiency: a 2-year open randomized controlled multicenter trial. J. Bone. Miner. Res. 17(6), 1081–1094 (2002). doi:10.1359/jbmr.2002.17.6.1081

    Article  CAS  PubMed  Google Scholar 

  34. M. Koltowska-Haggstrom, A.F. Mattsson, J.P. Monson, P. Kind, X. Badia, F.F. Casanueva, J. Busschbach, H.P. Koppeschaar, G. Johannsson, Does long-term GH replacement therapy in hypopituitary adults with GH deficiency normalise quality of life? Eur. J. Endocrinol. 155(1), 109–119 (2006). doi:10.1530/eje.1.02176

    Article  CAS  PubMed  Google Scholar 

  35. J.W. Tomlinson, N. Holden, R.K. Hills, K. Wheatley, R.N. Clayton, A.S. Bates, M.C. Sheppard, P.M. Stewart, Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet. 357(9254), 425–431 (2001). doi:10.1016/s0140-6736(00)04006-x

    Article  CAS  Google Scholar 

  36. T. Rosen, B.A. Bengtsson, Premature mortality due to cardiovascular disease in hypopituitarism. Lancet. 336(8710), 285–288 (1990). doi:10.1016/0140-6736(90)91812-O

    Article  CAS  PubMed  Google Scholar 

  37. S.M. Haffner, M.P. Stern, H.P. Hazuda, M. Rosenthal, J.A. Knapp, R.M. Malina, Role of obesity and fat distribution in non-insulin-dependent diabetes mellitus in Mexican Americans and non-Hispanic whites. Diabetes. Care. 9(2), 153–161 (1986)

    Article  CAS  Google Scholar 

  38. A.H. Kissebah, N. Vydelingum, R. Murray, D.J. Evans, A.J. Hartz, R.K. Kalkhoff, P.W. Adams, Relation of body fat distribution to metabolic complications of obesity. J. Clin. Endocrinol. Metab. 54(2), 254–260 (1982). doi:10.1210/jcem-54-2-254

    Article  CAS  PubMed  Google Scholar 

  39. M. Leonsson, J. Hulthe, J. Oscarsson, G. Johannsson, I. Wendelhag, J. Wikstrand, B.A. Bengtsson, Intima-media thickness in cardiovascularly asymptomatic hypopituitary adults with growth hormone deficiency: relation to body mass index, gender, and other cardiovascular risk factors. Clin. Endocrinol. 57(6), 751–759 (2002). doi:10.1046/j.1365-2265.2002.01663.x

    Article  Google Scholar 

  40. M. Pfeifer, R. Verhovec, B. Zizek, J. Prezelj, P. Poredos, R.N. Clayton, Growth hormone (GH) treatment reverses early atherosclerotic changes in GH-deficient adults. J. Clin. Endocrinol. Metab. 84(2), 453–457 (1999). doi:10.1210/jcem.84.2.5456

    Article  CAS  PubMed  Google Scholar 

  41. R.W. McCallum, J.R. Petrie, A.F. Dominiczak, J.M. Connell, Growth hormone deficiency and vascular risk. Clin. Endocrinol. 57(1), 11–24 (2002). doi:10.1111/j.1365-2265.2005.02245.x

    Article  CAS  Google Scholar 

  42. J.K. Devin, L.S. Blevins Jr., D.K. Verity, Q. Chen, J.R. Bloodworth Jr., J. Covington, D.E. Vaughan, Markedly impaired fibrinolytic balance contributes to cardiovascular risk in adults with growth hormone deficiency. J. Clin. Endocrinol. Metab. 92(9), 3633–3639 (2007). doi:10.1210/jc.2007-0609

    Article  CAS  PubMed  Google Scholar 

  43. S. Wakai, T. Fukushima, T. Furihata, K. Sano, Association of cerebral aneurysm with pituitary adenoma. Surg. Neurol. 12(6), 503–507 (1979)

    CAS  PubMed  Google Scholar 

  44. G. Brevetti, P. Marzullo, A. Silvestro, R. Pivonello, G. Oliva, C. di Somma, G. Lombardi, A. Colao, Early vascular alterations in acromegaly. J. Clin. Endocrinol. Metab 87(7), 3174–3179 (2002). doi:10.1210/jcem.87.7.8643

    Article  CAS  PubMed  Google Scholar 

  45. A. Poidvin, E. Touze, E. Ecosse, F. Landier, Y. Bejot, M. Giroud, P.M. Rothwell, J.C. Carel, J. Coste, Growth hormone treatment for childhood short stature and risk of stroke in early adulthood. Neurology. 83(9), 780–786 (2014). doi:10.1212/WNL.0000000000000737WNL.0000000000000737

    Article  CAS  PubMed  Google Scholar 

  46. V. Popovic, A.F. Mattsson, R.C. Gaillard, P. Wilton, M. Koltowska-Haggstrom, M.B. Ranke, Serum insulin-like growth factor I (IGF-I), IGF-binding proteins 2 and 3, and the risk for development of malignancies in adults with growth hormone (GH) deficiency treated with GH: data from KIMS (Pfizer international metabolic database). J. Clin. Endocrinol. Metab. 95(9), 4449–4454 (2010). doi:10.1210/jc.2010-0287jc.2010-0287

    Article  CAS  PubMed  Google Scholar 

  47. J.M. Chan, M.J. Stampfer, E. Giovannucci, P.H. Gann, J. Ma, P. Wilkinson, C.H. Hennekens, M. Pollak, Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Sci. 279(5350), 563–566 (1998)

    Article  CAS  Google Scholar 

  48. J. Ma, M. Pollak, E. Giovannucci, J.M. Chan, Y. Tao, C. Hennekens, M.J. Stampfer, A prospective study of plasma levels of insulin-like growth factor I (IGF-I) and IGF-binding protein-3, and colorectal cancer risk among men. Growth. Horm. IGF. Res. 10(Suppl A), S28–29 (2000)

    Article  Google Scholar 

  49. T.J. Key, P.N. Appleby, G.K. Reeves, A.W. Roddam, Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies. Lancet. Oncol. 11(6), 530–542 (2010). doi:10.1016/S1470-2045(10)70095-4S1470-2045(10)70095-4

    Article  PubMed  Google Scholar 

  50. E. Seccareccia, P. Brodt, The role of the insulin-like growth factor-I receptor in malignancy: an update. Growth. Horm. IGF. Res. 22(6), 193–199 (2012). doi:10.1016/j.ghir.2012.09.003S1096-6374(12)00085-8

    Article  CAS  PubMed  Google Scholar 

  51. C.A. Sklar, A.C. Mertens, P. Mitby, G. Occhiogrosso, J. Qin, G. Heller, Y. Yasui, L.L. Robison, Risk of disease recurrence and second neoplasms in survivors of childhood cancer treated with growth hormone: a report from the Childhood Cancer Survivor Study. J. Clin. Endocrinol. Metab. 87(7), 3136–3141 (2002). doi:10.1210/jcem.87.7.8606

    Article  CAS  PubMed  Google Scholar 

  52. B. Ergun-Longmire, A.C. Mertens, P. Mitby, J. Qin, G. Heller, W. Shi, Y. Yasui, L.L. Robison, C.A. Sklar, Growth hormone treatment and risk of second neoplasms in the childhood cancer survivor. J. Clin. Endocrinol. Metab. 91(9), 3494–3498 (2006). doi:10.1210/jc.2006-0656

    Article  CAS  PubMed  Google Scholar 

  53. B.C. Patterson, Y. Chen, C.A. Sklar, J. Neglia, Y. Yasui, A. Mertens, G.T. Armstrong, A. Meadows, M. Stovall, L.L. Robison, L.R. Meacham, Growth hormone exposure as a risk factor for the development of subsequent neoplasms of the central nervous system: a report from the childhood cancer survivor study. J. Clin. Endocrinol. Metab. 99(6), 2030–2037 (2014). doi:10.1210/jc.2013-4159

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. C.J. Child, D. Conroy, A.G. Zimmermann, W.W. Woodmansee, E.M. Erfurth, L.L. Robison, Incidence of primary cancers and intracranial tumour recurrences in GH-treated and untreated adult hypopituitary patients: analyses from the hypopituitary control and complications study. Eur. J. Endocrinol. 172(6), 779–790 (2015). doi:10.1530/EJE-14-1123EJE-14-1123

    Article  CAS  PubMed  Google Scholar 

  55. T.T. Chung, W.M. Drake, J. Evanson, D. Walker, P.N. Plowman, S.L. Chew, A.B. Grossman, G.M. Besser, J.P. Monson, Tumour surveillance imaging in patients with extrapituitary tumours receiving growth hormone replacement. Clin. Endocrinol. 63(3), 274–279 (2005). doi:10.1111/j.1365-2265.2005.02338.x

    Article  CAS  Google Scholar 

  56. A. Jostel, A. Mukherjee, P.A. Hulse, S.M. Shalet, Adult growth hormone replacement therapy and neuroimaging surveillance in brain tumour survivors. Clin. Endocrinol. 62(6), 698–705 (2005). doi:10.1111/j.1365-2265.2005.02282.x

    Article  CAS  Google Scholar 

  57. J.R. Arnold, D.F. Arnold, A. Marland, N. Karavitaki, J.A. Wass, GH replacement in patients with non-functioning pituitary adenoma (NFA) treated solely by surgery is not associated with increased risk of tumour recurrence. Clin. Endocrinol. 70(3), 435–438 (2009). doi:10.1111/j.1365-2265.2008.03391.xCEN3391

    Article  CAS  Google Scholar 

  58. N.J. Gittoes, A.S. Bates, W. Tse, B. Bullivant, M.C. Sheppard, R.N. Clayton, P.M. Stewart, Radiotherapy for non-function pituitary tumours. Clin. Endocrinol. 48(3), 331–337 (1998)

    Article  CAS  Google Scholar 

  59. M. Buchfelder, P.H. Kann, C. Wuster, U. Tuschy, B. Saller, G. Brabant, A. Kleindienst, P. Nomikos, Influence of GH substitution therapy in deficient adults on the recurrence rate of hormonally inactive pituitary adenomas: a case control study. Eur. J. Endocrinol. 157(2), 149–156 (2007). doi:10.1530/EJE-07-0164

    Article  CAS  PubMed  Google Scholar 

  60. A.G. Hatrick, P. Boghalo, J.B. Bingham, A.B. Ayres, P.H. Sonksen, D.L. Russell-Jones, Does GH replacement therapy in adult GH-deficient patients result in recurrence or increase in size of pituitary tumours? Eur. J. Endocrinol. 146(6), 807–811 (2002). doi:10.1530/eje.0.1460807

    Article  CAS  PubMed  Google Scholar 

  61. D.S. Olsson, M. Buchfelder, K. Wiendieck, N. Kremenevskaja, B.A. Bengtsson, K.E. Jakobsson, M. Jarfelt, G. Johannsson, A.G. Nilsson, Tumour recurrence and enlargement in patients with craniopharyngioma with and without GH replacement therapy during more than 10 years of follow-up. Eur. J. Endocrinol. 166(6), 1061–1068 (2012). doi:10.1530/EJE-12-0077EJE-12-0077

    Article  CAS  PubMed  Google Scholar 

  62. K. Stochholm, G. Johannsson, Reviewing the safety of GH replacement therapy in adults. Growth. Horm. IGF. Res. 25(4), 149–157 (2015). doi:10.1016/j.ghir.2015.06.006

    Article  CAS  PubMed  Google Scholar 

  63. C.C. van Bunderen, N.C. van Varsseveld, E.M. Erfurth, J.C. Ket, M.L. Drent, Efficacy and safety of growth hormone treatment in adults with growth hormone deficiency: a systematic review of studies on morbidity. Clin. Endocrinol. 81(1), 1–14 (2014). doi:10.1111/cen.12477

    Article  CAS  Google Scholar 

  64. S. Mackenzie, T. Craven, H.R. Gattamaneni, R. Swindell, S.M. Shalet, G. Brabant, Long-term safety of growth hormone replacement after CNS irradiation. J. Clin. Endocrinol. Metab. 96(9), 2756–2761 (2011). doi:10.1210/jc.2011-0112

    Article  CAS  PubMed  Google Scholar 

  65. D.S. Olsson, M. Buchfelder, S. Schlaffer, B.A. Bengtsson, K.E. Jakobsson, G. Johannsson, A.G. Nilsson, Comparing progression of non-functioning pituitary adenomas in hypopituitarism patients with and without long-term GH replacement therapy. Eur. J. Endocrinol. 161(5), 663–669 (2009). doi:10.1530/EJE-09-0572

    Article  CAS  PubMed  Google Scholar 

  66. H. Holmer, J. Svensson, L. Rylander, G. Johannsson, T. Rosen, B.A. Bengtsson, M. Thoren, C. Hoybye, M. Degerblad, M. Bramnert, E. Hagg, B. Eden Engstrom, B. Ekman, B. Norrving, L. Hagmar, E.M. Erfurth, Nonfatal stroke, cardiac disease, and diabetes mellitus in hypopituitary patients on hormone replacement including growth hormone. J. Clin. Endocrinol. Metab. 92(9), 3560–3567 (2007). doi:10.1210/jc.2007-0458

    Article  CAS  PubMed  Google Scholar 

  67. A.J. Swerdlow, C.D. Higgins, P. Adlard, M.A. Preece, Risk of cancer in patients treated with human pituitary growth hormone in the UK, 1959–85: a cohort study. Lancet. 360(9329), 273–277 (2002)

    Article  CAS  Google Scholar 

  68. G. Mardh, A. Lindeberg, Growth hormone replacement therapy in adult hypopituitary patients with growth hormone deficiency: combined clinical safety data from clinical trials in 665 patients. Endocrinol. Metab. 2(Suppl B), 11–16 (1995)

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Endocrinology, Diabetes, Metabolism, & Nutrition, Mayo Clinic, Rochester, MN, USA

    Sina Jasim, Shrikant U. Tamhane, Anu Sharma, Diane Donegan & Todd B. Nippoldt

  2. Mayo Clinic Evidence-Based Practice Center, Rochester, MN, USA

    Fares Alahdab, Ahmed T. Ahmed & M. Hassan Murad

Authors
  1. Sina Jasim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fares Alahdab
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ahmed T. Ahmed
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shrikant U. Tamhane
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Anu Sharma
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Diane Donegan
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Todd B. Nippoldt
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M. Hassan Murad
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Hassan Murad.

Ethics declarations

Conflict of interest

The authors declare that they have no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jasim, S., Alahdab, F., Ahmed, A.T. et al. The effect of growth hormone replacement in patients with hypopituitarism on pituitary tumor recurrence, secondary cancer, and stroke. Endocrine 56, 267–278 (2017). https://doi.org/10.1007/s12020-016-1156-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12020-016-1156-6

Keywords

Search

Navigation